These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30038488)

  • 1. Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.
    Huang J; Yuan X; Pang Q; Zhang H; Yu J; Yang B; Zhou L; Zhang F; Liu F
    Drug Des Devel Ther; 2018; 12():2223-2231. PubMed ID: 30038488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
    Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
    Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma.
    Zhang SX; Qiu QH; Chen WB; Liang CH; Huang B
    Cell Physiol Biochem; 2014; 33(5):1484-97. PubMed ID: 24854838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
    Alqahtani AM; Chidambaram K; Pino-Figueroa A; Chandrasekaran B; Dhanaraj P; Venkatesan K
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1916-1927. PubMed ID: 33660801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.
    Akashi Y; Okamoto I; Iwasa T; Yoshida T; Suzuki M; Hatashita E; Yamada Y; Satoh T; Fukuoka M; Ono K; Nakagawa K
    Br J Cancer; 2008 Feb; 98(4):749-55. PubMed ID: 18253126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells.
    Wang J; Chang L; Lai X; Li X; Wang Z; Huang Z; Huang J; Zhang G
    Cell Cycle; 2018; 17(6):671-680. PubMed ID: 29285984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects and its mechanism of Nimotuzumab on radiosensitivity of esophageal carcinoma ECA-109 and TE-13 cell lines].
    Wang J; Wang W; Guo Y; Jing SW; Shang K; Miao MC; Wang J; Wu YJ; Liu LN; Yu JM
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):732-738. PubMed ID: 27784455
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
    Liang R; Yang L; Zhu X
    Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
    Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
    Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
    Bhuvaneswari R; Ng QF; Thong PS; Soo KC
    Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma.
    Yu Y; Guan H; Jiang L; Li X; Xing L; Sun X
    Int J Oncol; 2020 Apr; 56(4):945-956. PubMed ID: 32319582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
    Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
    Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.
    Qu YY; Hu SL; Xu XY; Wang RZ; Yu HY; Xu JY; Chen L; Dong GL
    PLoS One; 2013; 8(8):e70727. PubMed ID: 23976954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeic acid phenethyl ester suppressed growth and metastasis of nasopharyngeal carcinoma cells by inactivating the NF-κB pathway.
    Liang Y; Feng G; Wu L; Zhong S; Gao X; Tong Y; Cui W; Qin Y; Xu W; Xiao X; Zhang Z; Huang G; Zhou X
    Drug Des Devel Ther; 2019; 13():1335-1345. PubMed ID: 31118570
    [No Abstract]   [Full Text] [Related]  

  • 17. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
    Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
    Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
    Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
    J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Gowda R; Sharma A; Robertson GP
    Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.